Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830] (Annals of Oncology (2019) 30(11) (1821–1830), (S0923753420325904))

K. L. Jhaveri, X. V. Wang, V. Makker, S. W. Luoh, E. P. Mitchell, J. A. Zwiebel, E. Sharon, R. J. Gray, S. Li, L. M. McShane, L. V. Rubinstein, D. Patton, P. M. Williams, S. R. Hamilton, B. A. Conley, C. L. Arteaga, L. N. Harris, P. J. O'Dwyer, A. P. Chen, K. T. Flaherty

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830] (Annals of Oncology (2019) 30(11) (1821–1830), (S0923753420325904))'. Together they form a unique fingerprint.

Medicine & Life Sciences